基于mRNA的尿液检测在血尿患者中筛查膀胱癌的验证
本研究在前瞻性多中心队列中验证Xpert膀胱癌检测(Xpert)在血尿患者中的性能。Xpert对高级别肿瘤敏感性90%,总体阴性预测值98%,特异性84%,敏感性和阴性预测值优于细胞学和UroVysion。Xpert有望识别低风险膀胱癌血尿患者,避免不必要的膀胱镜检查。
要点
- Xpert对高级别膀胱癌敏感性90%,总体阴性预测值98%。
- Xpert敏感性和阴性预测值优于尿细胞学和UroVysion。
- Xpert或可帮助筛选低风险血尿患者避免膀胱镜。
核心结论
- Xpert是一种易用、无创的尿液检测,相比细胞学和UroVysion具有更高的敏感性和阴性预测值。
- Xpert有望识别膀胱癌可能性极低的血尿患者,可能避免膀胱镜检查。
研究设计与样本
- 前瞻性多中心研究,在22个中心连续收集因血尿行膀胱镜检查且无膀胱癌病史患者的排尿后膀胱镜前尿液标本。
- 共纳入828例患者(平均年龄64.5岁,男性467例,从不吸烟者401例)。
- 同时进行Xpert、尿细胞学和UroVysion检测,并以膀胱镜和组织学结果计算检测特征。
- 另外在良性前列腺增生和前列腺癌患者中进行了特异性研究。
主要发现
- Xpert总体敏感性78%(95%CI 66-87),高级别肿瘤敏感性90%(95%CI 76-96)。
- Xpert总体阴性预测值98%(95%CI 97-99),特异性84%(95%CI 81-86)。
- 在微量血尿患者中,仅漏诊1例高级别肿瘤,阴性预测值99%。
- Xpert的敏感性和阴性预测值高于尿细胞学和UroVysion;细胞学特异性最高(97%)。
- 在单独的特异性研究中,Xpert在良性前列腺增生患者中特异性89%,在前列腺癌患者中特异性92%。
临床怎么用
- 对于血尿患者,Xpert可作为无创检测用于评估膀胱癌风险。
- Xpert高阴性预测值有助于识别可能不需要膀胱镜检查的低风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with haematuria, a fast, noninvasive test with high sensitivity (SN) and negative predictive value (NPV), which is able to detect or exclude bladder cancer (BC), is needed. A newly developed urine assay, Xpert Bladder Cancer Detection (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC. OBJECTIVE: To validate the performance of Xpert in patients with haematuria. DESIGN, SETTING, AND PARTICIPANTS: Voided precystoscopy urine specimens were prospectively collected at 22 sites from patients without prior BC undergoing cystoscopy for haematuria. Xpert, cytology, and UroVysion procedures were performed. Technical validation was performed and specificity (SP) was determined in patients without BC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Test characteristics were calculated based on cystoscopy and histology results, and compared between Xpert, cytology, and UroVysion. RESULTS AND LIMITATIONS: We included 828 patients (mean age 64.5 yr, 467 males, 401 never smoked). Xpert had an SN of 78% (95% confidence interval [CI]: 66-87) overall and 90% (95% CI: 76-96) for high-grade (HG) tumours. The NPV was 98% (95% CI: 97-99) overall. The SP was 84% (95% CI: 81-86). In patients with microhaematuria, only one HG patient was missed (NPV 99%). Xpert had higher SN and NPV than cytology and UroVysion. Cytology had the highest SP (97%). In a separate SP study, Xpert had an SP of 89% in patients with benign prostate hypertrophy and 92% in prostate cancer patients. CONCLUSIONS: Xpert is an easy-to-use, noninvasive test with improved SN and NPV compared with cytology and UroVysion, representing a promising tool for identifying haematuric patients with a low likelihood of BC who might not need to undergo cystoscopy. PATIENT SUMMARY: Xpert is an easy-to-perform urine test with good performance compared with standard urine tests. It should help identify (micro)haematuria patients with a very low likelihood to have bladder cancer.
引用
- Valenberg FJPV, Hiar AM, Wallace E, et al. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. Eur Urol Oncol. 2020. PMID: 33004290. doi:10.1016/j.euo.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。